The Clinicopathological Spectrum of Follicle Cell-Derived Thyroid Neoplasms in A Tertiary Care Hospital as Per New WHO Classification 2022 (5th EDITION)

Nabeel Mazhar; Syed Salman  Ali; Bushra  Parveen; Wajahat Ahmed  Khan; Aysha  Aslam; Hafiz Muhammad Hamza  Arshad

doi:10.51253/pafmj.v76i5.13778

Authors

Nabeel Mazhar Department of Histopathology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Syed Salman Ali Department of Histopathology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Bushra Parveen Department of Histopathology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Wajahat Ahmed Khan Department of Histopathology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Aysha Aslam Department of Histopathology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Hafiz Muhammad Hamza Arshad Department of Histopathology, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76i5.13778

Keywords:

Follicular Thyroid Carcinoma, High-Grade Thyroid Carcinoma, Papillary Thyroid Carcinoma, Thyroid Follicular Nodular Disease.

Abstract

Objective: To find the spectrum of follicle cell-derived neoplasms as per new WHO classification of the thyroid gland neoplasm.

Study Design: Cross sectional study

Place and Duration of Study: Histopathology Department, Armed Forces Institute of Pathology, Rawalpindi Pakistan, from Jun to Dec 2023.

Methodology: A total of 100 follicular cell–derived thyroid tumor cases received at histopathology department AFIP, Rawalpindi were analyzed in this study. Demographic data was recorded from the lab submission form and written informed consent was taken after contacting patients. Statistical analysis was accomplished using SPSS version 25.

Results: A total of 100 cases of follicular cell derived thyroid neoplasms were included. Mean age of patients was 45.77±12.78 years range from 22 to 78 years. Majority of patients were females 71.0% as compared to males 29.0%. Multifocal tumors were seen in 81.0% cases while unifocal in 19% cases. Follicular nodular disease was the most common entity found in benign neoplasms 77% followed by papillary thyroid carcinoma (PTC) (10.0%). Newer entity differentiated high-grade thyroid carcinoma (DHGTC), was found in 4.0% of cases. Hurthle cell neoplasm accounted for 6.0% while poorly differentiated thyroid carcinoma was observed in 3.0% of cases. The a statistically significant association was found between tumor type and tumor grade (p-value <0.001) and tumor focality (p-value =0.024). The Ki-67 index increased significantly with tumor dedifferentiation as (p<0.001)

Conclusion: According to the updated WHO classification, follicular nodular disease has become the most prevalent benign neoplasm of thyroid follicular cell origin. Careful application ..

Downloads

Download data is not yet available.

References

1. Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs 4th ed. Lyon: International Agency for Research on Cancer; 2017.

2. WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2022.

3. Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung C K, et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocrine Pathol 2022; 33(1): 27–63.

https://doi.org/10.1007/s12022-022-09721-4

4. Hellgren LS, Stenman A, Paulsson JO, Hoog A, Larsson C, Zedenius J, et al. Prognostic utility of the Ki-67 labeling index in follicular thyroid tumors: A 20-year experience from a tertiary thyroid center. Endocrine Pathol 2022; 33(2): 231–242.

https://doi.org/10.1007/s12022-022-09741-0

5. Hafeez K, Zafar A, Afzal M, Javed A, Aftab A. Frequency of papillary carcinoma in patients with solitary thyroid nodule. Pak J Med Health Sci 2021; 15(2): 406–409.

https://doi.org/10.1016/j.envpol.2018.08.036

6. Abrishami G, Emadzadeh M, Bakhshi A, Moeinipour Y, Taghav G, Hasani, S. Prevalence and predictors of thyroid nodules among adults: analyzing the association with metabolic syndrome in a cross-sectional study. BMC endocrine disord 2025; 25(1): 40.

https://doi.org/10.1186/s12902-025-01869-5

7. Rossi ED, Pantanowitz L, Hornick JL. A worldwide journey of thyroid cancer incidence centred on tumour histology. Lancet 2021; 9(4): 193–194.

https://doi.org/10.1016/S2213-8587(21)00049-8

8. Gao MZ, Omer TM, Miller KM, Simpson MC, Bukatko AR., Gedion K, et al. Thyroid cancer incidence and trends in United States and Canadian pediatric, adolescent, and young adults. Cancers 2025; 17(9): 1429.

https://doi.org/10.3390/cancers17091429

9. Poma AM, Macerola E, Ghossein RA, Tallini G, Basolo F. Prevalence of Differentiated High-Grade Thyroid Carcinoma Among Well-Differentiated Tumors: A Systematic Review and Meta-Analysis. Thyroid 2024; 34(3): 314–323.

https://doi.org/10.1089/thy.2023.0350

10. Kitahara CM, Sosa JA. (2020). Understanding the ever-changing incidence of thyroid cancer. Nat Rev Endocrinol 2020; 16(11): 617–618. https://doi.org/10.1038/s41574-020-00414-9

11. Xie J. Research progress on estrogen and estrogen receptors in thyroid cancer. J Steroid Biochem Mol Biol 2025; 211: 105905.

https://doi.org/10.1016/j.jsbmb.2025.105905

12. Haugen BR, Alexander EK, Bible KC, Doherty GM. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26(1): 1–133.

https://doi.org/10.1089/thy.2015.0020

13. Nixon I J, Ganly I, Patel SG, Palmer FL, Whitcher MM, Tuttle RM. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surg 2012; 151(4): 571–579.

https://doi.org/10.1016/j.surg.2011.08.016

14. Zafon C, Obiols G, Castellví J, Tallada N, Baena J A, Simó R. Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma. Histopathology 2007; 50(2): 225–231. https://doi.org/10.1111/j.1365-2559.2006.02555.x

15. Park Y M, Lee YJ, Kim S H, Kim J H, Bae J S, Park, G. S, et al. Clinical implications of the Ki-67 labeling index and cytokeratin 19 expression in papillary thyroid carcinoma. J Korean Med Sci 2017; 32(12): 2051–2056.

https://doi.org/10.3346/jkms.2017.32.12.2051

16. Hirokawa M, Kudo T, Ota H, Shimizu K, Yabuta T, Fukushima M, et al. Ki-67 labeling index in encapsulated follicular tumors: A simple predictor of patient outcomes. Endocrine J 2020; 67(1): 45–51. https://doi.org/10.1507/endocrj.EJ19-0383

17. Oh H. S, Ha J, Kim H. I, Kim T. H, Kim W G, et al. Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma: A Multi-Center Cohort Study in Korea. Thyroid :J Am Thyroid Assoc 2018; 28(12): 1587–1594.

https://doi.org/10.1089/thy.2018.0263

18. Fagin JA, Wells SA. Biologic and Clinical Perspectives on Thyroid Cancer. N Eng j med 2016; 375(11): 1054–1067.

https://doi.org/10.1056/NEJMra1501993

19. Gandolfi G, Sancisi V, Piana S, Ciarrocchi A. Molecular pathology of thyroid tumors. Front Endocrinol 2022; 13: 853186.

https://doi.org/10.3389/fendo.2022.853186

20. Pusztaszeri, M, Bongiovanni, M, Faquin WC. Update on the cytologic and molecular features of thyroid nodules: Review of the literature. Clin Lab Med 2018; 38(2): 287–308.

https://doi.org/10.1016/j.cll.2018.02.004